Lilly Global CEO: plans to launch 30 new products in China and hopes to cooperate with Chinese innovative pharmaceutical companies

Nine years later, David A ricks came to China again, but by this time his identity had become Lilly's New Global CEO and president How will the new CEO, born in the market, position Lilly's global market strategy, and what is his targeted plan for the Chinese market? On March 18, David A ricks, a 49 year old American, attended the 2017 China development high level forum in Beijing for the first time as CEO of Lilly global This place is no stranger to him, because nine years ago, he served as president and general manager of Lilly China, the fastest-growing branch of Lilly in the global emerging markets, adding color to his resume Three months ago, he emerged from the internal selection to replace Li Lida as the new global president and CEO of the 141 year old multinational pharmaceutical company Dai Wenrui was born in the first-line marketing department, decisive and direct He sat down in the conference room of Diaoyutai State Guesthouse He asked for a cup of green tea instead of the usual black coffee He accepted an hour's interview with the e-medicine manager reporter The topic began from the changes and changelessness of the Chinese market he felt in the past nine years According to the statistics of the Ministry of industry and information technology, in 2016, the industrial added value of the pharmaceutical industry increased by 10.4% year on year, the fastest growth in all 12 industries In recent years, the rise of a number of local new drug innovation enterprises has also attracted great attention of Dai Wenrui, including many local projects participated by Lilly Asia venture capital fund In his view, the emergence of such a group of start-ups is a manifestation of the increasingly perfect Chinese pharmaceutical ecology The incidence rate of chronic diseases is still rising in China, which makes Lilly focusing on diabetes and other fields China's market needs for new drugs are still very large According to the plan, Lilly is expected to launch about 20 new drugs worldwide from 2015 to 2023 Specific to the Chinese market, it is planned to introduce 30 new products (including new indications and new dosage forms) in the next 10 years On the other hand, "yesterday I had an exchange with several famous experts in the field of cancer and diabetes in China, and discussed the reform of public hospitals very warmly But I think this reform is very complicated, so it will definitely take a long time " Dai said Structural adjustment: Since China's promotion, many multinational pharmaceutical enterprises have adjusted the global organizational structure, including Lilly, which is a country that has been designated as a key one "Now, China, Japan and the United States, as the three core markets of Lilly in the world, report directly to Lilly headquarters," said Dai And diabetes, tumor and cross biochemical fields are the three most important treatment fields of Lilly, which are operated by a separate business unit " By canceling the intermediate level and reporting directly to the headquarters, Dai believes that such adjustment will further improve the operation efficiency of China, be closer to the Chinese market from a global level, and make decision-making and action faster From 2010, several important product patents of Lilly in the U.S market have expired, and Li Lida, the retired former CEO, admitted that it was the hardest time for Lilly "During the difficult period of the company in the past few years, the Chinese market has played an important role in both sales growth and product performance." Although Dai did not disclose the specific figures of Lilly's performance in China, the importance of the Chinese market to Lilly is self-evident What's the next hickory? In 2016, Lilly announced the distribution and promotion of its antibiotic products in the Chinese mainland market to Yiteng, which is also the fifth case last year for multinational pharmaceutical companies to carry out commercial cooperation between product lines and local enterprises The cooperation agreement officially started on January 1, 2017 The question is, will Lilly have the next product to sell China's rights and interests for strategic reasons? For Lilly, both hickory and stable and reliable are the old drugs that have been listed on the Chinese market for more than 20 years, and their market performance is also excellent However, with the increasing competition in the Chinese antibiotic market, the market pressure of these two products is gradually increasing The original intention of Lilly's cooperation with Yiteng is to sell the old brand products and focus its resources more on the existing R & D product line, so as to develop more innovative drugs "From the current situation, we are satisfied with this cooperation." He ander, President of Lilly China, didn't immediately make a conclusion on the cooperation He said it would take several months to see the real results As for whether there will be similar cooperation plans in the future, he said that for other products, Lilly itself has sufficient resources to complete the distribution work In recent years, in order to expand its influence in the Chinese market, Lilly has carried out a number of cooperation with local enterprises in the joint research and development of new drugs and commercial sales, so as to expand the coverage of Lilly products in the Chinese market In September 2016, rituximab injection, a bio generic drug jointly developed by Lilly and Cinda pharmaceutical, was approved by CFDA, and the phase I safety study of the drug has also been completed The drug originated from the cooperative development agreement reached by Cinda and Lilly in March 2015 The two sides jointly developed three potential tumor treatment drugs in China and the world, one provided by Lilly and two provided by Cinda Only half a year later, Lilly and Cinda reached another global development cooperation agreement with a total milestone payment of more than US $1 billion, which is the largest amount involved in the international cooperation project of new drugs in China so far, including three tumor immunotherapy bispecific antibody drugs "We are very willing to cooperate with China's innovative pharmaceutical enterprises, which will not only help Lilly bring global product line products into China, but also improve the drug accessibility for Chinese patients The progress made in cooperation with Cinda proves that we have chosen the right path " So said Dai Wenrui At the beginning of this year, Lilly bought back the pain medicine for 960 million US dollars to acquire the migraine medicine lasmiditan from the biotechnology company colucid, which is also Lilly's first sale in the M & a market this year In fact, the drug was originally discovered by Lilly, but since "pain was not the focus of the company's research and development", Lilly transferred it to colucid in 2005 In recent years, the field of pain is rising Lilly has realized the significance of developing migraine drugs It is understood that lasmiditan has entered the late stage of R & D, and can start to apply for registration and listing after the last clinical trial in the second half of this year "This is a new drug with transformative significance, and we hope to have greater development in the field of pain treatment." Lilly's acquisition style has never been large-scale and large amount In Dai Wenrui's plan, Lilly's acquisition target must be innovative products, which can supplement and contribute to the existing product line The ongoing new drug R & D projects and promising new drug R & D enterprises will be the focus of Lilly's attention On the contrary, for large-scale M & A, Dai believes that M & A involving a large amount of capital may damage the value of the company.